DK1337247T3 - Anvendelse af Gaboxadol til behandling af præmenstruel forstyrrelse, födselsdepression eller postmenopausalt relateret disforisk forstyrrelse - Google Patents

Anvendelse af Gaboxadol til behandling af præmenstruel forstyrrelse, födselsdepression eller postmenopausalt relateret disforisk forstyrrelse

Info

Publication number
DK1337247T3
DK1337247T3 DK01996378T DK01996378T DK1337247T3 DK 1337247 T3 DK1337247 T3 DK 1337247T3 DK 01996378 T DK01996378 T DK 01996378T DK 01996378 T DK01996378 T DK 01996378T DK 1337247 T3 DK1337247 T3 DK 1337247T3
Authority
DK
Denmark
Prior art keywords
disorder
gaboxadol
birth
depression
postmenopausal
Prior art date
Application number
DK01996378T
Other languages
English (en)
Inventor
Bjarke Ebert
Andersen Peter Hongaard
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8159857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1337247(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of DK1337247T3 publication Critical patent/DK1337247T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
DK01996378T 2000-11-20 2001-11-20 Anvendelse af Gaboxadol til behandling af præmenstruel forstyrrelse, födselsdepression eller postmenopausalt relateret disforisk forstyrrelse DK1337247T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200001743 2000-11-20

Publications (1)

Publication Number Publication Date
DK1337247T3 true DK1337247T3 (da) 2006-12-04

Family

ID=8159857

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01996378T DK1337247T3 (da) 2000-11-20 2001-11-20 Anvendelse af Gaboxadol til behandling af præmenstruel forstyrrelse, födselsdepression eller postmenopausalt relateret disforisk forstyrrelse

Country Status (33)

Country Link
US (2) US20040024038A1 (da)
EP (1) EP1337247B1 (da)
JP (1) JP4152186B2 (da)
KR (1) KR100865651B1 (da)
CN (1) CN1318027C (da)
AR (1) AR031473A1 (da)
AT (1) ATE336242T1 (da)
AU (2) AU2351402A (da)
BG (1) BG107909A (da)
BR (1) BR0115668A (da)
CA (1) CA2429220C (da)
CY (1) CY1106209T1 (da)
CZ (1) CZ20031383A3 (da)
DE (1) DE60122368T2 (da)
DK (1) DK1337247T3 (da)
EA (1) EA007287B1 (da)
ES (1) ES2266308T3 (da)
HR (1) HRP20030404A2 (da)
HU (1) HUP0400505A3 (da)
IL (1) IL155587A0 (da)
IS (1) IS2427B (da)
ME (1) MEP6408A (da)
MX (1) MXPA03004349A (da)
NO (1) NO20032271L (da)
NZ (1) NZ525520A (da)
PL (1) PL361051A1 (da)
PT (1) PT1337247E (da)
SI (1) SI1337247T1 (da)
SK (1) SK7682003A3 (da)
UA (1) UA77403C2 (da)
WO (1) WO2002040009A1 (da)
YU (1) YU39003A (da)
ZA (1) ZA200303289B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CN1615146A (zh) * 2001-11-26 2005-05-11 芬策尔贝格有限两合公司 生姜提取物制剂
EP1641456B1 (en) * 2003-06-25 2010-03-03 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
AU2004324938A1 (en) * 2004-06-29 2006-05-26 H. Lundbeck A/S Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis
WO2006012563A2 (en) * 2004-07-23 2006-02-02 The Regents Of The University Of California Method for the treatment and diagnosis of certain psychiatric disorders related to the menstrual cycle
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
US20070122507A1 (en) * 2005-05-26 2007-05-31 Palu Afa K Histone deacetylase and tumor necrosis factor converting enzyme inhibition
US9209995B2 (en) * 2006-12-29 2015-12-08 Prodea Systems, Inc. Presence status notification from digital endpoint devices through a multi-services gateway device at the user premises
WO2008141112A1 (en) * 2007-05-09 2008-11-20 Cenerx Biopharma, Inc. Methods of treating rett syndrome
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
CN103547240B (zh) * 2011-06-16 2016-03-30 索雷斯生命科学公司 用于人类自主神经系统的平衡和维持健康的系统和方法
RU2496496C1 (ru) * 2012-10-04 2013-10-27 Исаак Григорьевич Гитлин Фармацевтическая композиция, обладающая гамк-ергической активностью
KR20240160666A (ko) 2015-07-17 2024-11-11 오비드 테라퓨틱스 인크. 가복사돌로 발달장애들을 치료하는 방법들
EP4233861A3 (en) * 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR102049522B1 (ko) * 2018-06-05 2019-11-27 충남대학교산학협력단 Gaba를 유효성분으로 하는 살모넬라 감염질환의 예방 및 치료용 조성물
KR102049526B1 (ko) * 2018-06-05 2019-11-27 충남대학교산학협력단 Gaba를 유효성분으로 하는 항결핵 약학 조성물
AU2019345312A1 (en) 2018-09-20 2021-03-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
WO2020106927A1 (en) 2018-11-21 2020-05-28 Certego Therapeutics Gaboxadol for reducing risk of suicide and rapid relief of depression
CN113423399A (zh) 2018-12-17 2021-09-21 奥维德医疗公司 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療
WO2021127308A1 (en) 2019-12-18 2021-06-24 Ovid Therapeutics Inc. GABOXADOL FOR THERAPEUTIC TREATMENT OF 1p36 DELETION SYNDROME
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
CN114404437A (zh) * 2022-03-15 2022-04-29 山东中医药大学 没食子酰芍药苷在制备gabaa受体抑制剂中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362731A (en) * 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
JPH06510999A (ja) * 1991-09-13 1994-12-08 コセンシス・インコーポレイテッド ステロイド結合部位を有する新規ＧＡＢＡ↓ａレセプター
US5206415A (en) * 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
CZ300694A3 (en) * 1993-12-02 1996-05-15 Akzo Nobel Nv Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
AP653A (en) * 1994-11-23 1998-07-21 Cocensys Inc Androstane and pregnane series for allosteric modulations of gaba receptor.
US5776959A (en) * 1995-06-05 1998-07-07 Washington University Anticonvulsant and anxiolytic lactam and thiolactam derivatives
EP1288220A3 (en) * 1995-06-06 2004-07-21 Euro-Celtique Neuroactive 3.alpha.-hydroxy-steroids of the androstane and pregnane series
IT1290003B1 (it) * 1997-03-03 1998-10-19 Angelini Ricerche Spa Uso di pivagabina per preparare composizioni farmaceutiche
GB9801208D0 (en) * 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
KR100599142B1 (ko) * 1998-07-22 2006-07-12 악조 노벨 엔.브이. α- 아미노산 페닐 에스테르 유도체
AU1808401A (en) * 1999-12-08 2001-06-18 Warner-Lambert Company Method for the stereoselective synthesis of cyclic amino acids

Also Published As

Publication number Publication date
CY1106209T1 (el) 2011-06-08
US20090143435A1 (en) 2009-06-04
AU2002223514B2 (en) 2006-11-30
PL361051A1 (en) 2004-09-20
IS6803A (is) 2003-04-30
EA200300594A1 (ru) 2003-10-30
AU2351402A (en) 2002-05-27
PT1337247E (pt) 2006-11-30
SK7682003A3 (en) 2003-10-07
MEP6408A (xx) 2010-02-10
MXPA03004349A (es) 2003-08-19
EP1337247A1 (en) 2003-08-27
ES2266308T3 (es) 2007-03-01
CN1318027C (zh) 2007-05-30
ZA200303289B (en) 2005-07-27
CZ20031383A3 (cs) 2003-08-13
NO20032271D0 (no) 2003-05-20
SI1337247T1 (sl) 2006-12-31
US20040024038A1 (en) 2004-02-05
IL155587A0 (en) 2003-11-23
ATE336242T1 (de) 2006-09-15
IS2427B (is) 2008-10-15
BR0115668A (pt) 2003-09-02
DE60122368T2 (de) 2007-08-09
KR100865651B1 (ko) 2008-10-29
HUP0400505A3 (en) 2008-08-28
HK1075010A1 (en) 2005-12-02
CN1592616A (zh) 2005-03-09
DE60122368D1 (de) 2006-09-28
WO2002040009A1 (en) 2002-05-23
YU39003A (sh) 2006-05-25
AR031473A1 (es) 2003-09-24
EP1337247B1 (en) 2006-08-16
BG107909A (bg) 2004-08-31
JP2004513921A (ja) 2004-05-13
NZ525520A (en) 2005-04-29
CA2429220C (en) 2009-09-15
CA2429220A1 (en) 2002-05-23
HRP20030404A2 (en) 2005-04-30
NO20032271L (no) 2003-05-20
JP4152186B2 (ja) 2008-09-17
HUP0400505A2 (hu) 2004-07-28
KR20030065517A (ko) 2003-08-06
EA007287B1 (ru) 2006-08-25
UA77403C2 (en) 2006-12-15

Similar Documents

Publication Publication Date Title
ATE336242T1 (de) Verwendung von gaboxadol zur behandlung von premenstruelle störung, postnatal depression oder postmenopausal-bedingte-dysphorische störung
DK1259218T3 (da) Kosmetisk sammensætning til behandling af aldrende og/eller stresset hud
NO2016006I1 (no) Prodroger av fosfonatnukleotidanaloger,preparat derav og dets anvendelse til terapeutisk og profylaktisk behandling av virusinfeksjoner
ATE354360T1 (de) Amidoacetonitrile zur bekämpfung von endoparasiten
ATE473944T1 (de) Mittel zur wasserbehandlung
NO20035325D0 (no) Hudpermeabelt selektiv cyklooksygenase-2-inhibitorpreparat
CL2005002823A1 (es) Anticuerpos anti-virus respiratorio sincitial, antigenos y usos de los mismos
DE50111921D1 (de) Atmungsfreie Membraneinspannung
NO2012018I1 (no) Canakinumab eller direkte ekvivalenter derav
DE60128186D1 (de) Abgasreinigungskatalysator
DE60144321D1 (de) Abgasreinigungskatalysator
BR0113798A (pt) Derivados de resorcinol
DE50103557D1 (de) Assistenzsystem zur auswahl von strecken
DE60109617D1 (de) Katalysator zur rekombination von wasserstoff
DE60138513D1 (de) Abgasreinigungskatalysator
DE60138984D1 (de) Abgasreinigungskatalysator
DE60223576D1 (de) Hautbehandlungszusammensetzung
DK1303265T3 (da) Anvendelse af COX-2-inhibitorer, som immunostimulerende midler ved behandling af HIV eller AIDS
EP1628761A4 (en) PREPARATION OF A PHOSPHORUS / VANADIUM CATALYST
DE60132362D1 (de) Herstellung von ultradünnwandigen cordierit-strukturen
IS7035A (is) Örhylki til að halda andardrætti ferskum
DE50108607D1 (de) Verfahren zur Herstellung von 4-Aminodiphenylamin
EE05444B1 (et) FSH kasutamine viljatuse raviks
DK1461042T3 (da) Anvendelse af desoxypeganin til behandling af klinisk depression
DE602004013599D1 (de) Herstellung von somatostatinpeptiden